Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Desmethyl cariprazine prodrug - Abbvie

Next Previous
Drug Profile

Desmethyl cariprazine prodrug - Abbvie

Alternative Names: ABBV-932; RGH-932

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gedeon Richter
  • Developer AbbVie; Gedeon Richter
  • Class Antidepressants; Anxiolytics; Mood stabilisers; Small molecules
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bipolar depression; Generalised anxiety disorder
  • Phase I Bipolar disorders; Unspecified

Most Recent Events

  • 15 Jul 2025 AbbVie initiates a phase I trial (In volunteers, Combination therapy) (PO) (NCT07071532)
  • 08 Jul 2025 AbbVie plans a phase I trial (In volunteers, Combination therapy) (PO), in July 2025 (NCT07071532)
  • 17 Jun 2025 AbbVie plans phase-I pharmacokinetics and safety trial (In volunteers) in August 2025 (PO, Capsule) (NCT07024797)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top